Quantcast

Latest Syndromes Stories

2014-07-31 16:29:24

AZ-002 Phase 2a Study in Patients with Epilepsy Planned for Second Half of 2014 MOUNTAIN VIEW, Calif., July 31, 2014 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today provided an update on its pipeline and new product development efforts. In the second half of 2014, Alexza expects to initiate a Phase 2a study of AZ-002 (Staccato(®) alprazolam), which is being developed for the management of patients with acute repetitive seizures. Additionally, Alexza has...

2014-07-30 23:02:12

EDNF Installs 2014-2015 Board of Directors McLean, VA (PRWEB) July 30, 2014 The Ehlers-Danlos National Foundation (EDNF) is pleased to announce its 2014-2015 Board of Directors. Sandra Aiken Chack will serve as chair. The board was voted upon earlier this month at the EDNF 2014 Annual Learning Conference in Houston, Texas July 10-12. “The Ehlers-Danlos National Foundation has an ambitious agenda ahead of us. From the rollout of the first EDNF Center for Clinical Care & Research at...

2014-07-23 12:31:13

MELBOURNE, Australia, July 23, 2014 /CNW/ - The Honourable Rona Ambrose, Minister of Health, participated in the 20(th) International AIDS Conference this week in Melbourne, Australia. During the Conference sessions, meetings and side events, Minister Ambrose reinforced Canada's continued commitment to global efforts to address HIV/AIDS and to advancing a comprehensive and integrated long-term approach to address HIV/AIDS in Canada. While in Melbourne, Minister Ambrose toured the...

2014-07-23 08:32:06

ATLANTA, July 23, 2014 /PRNewswire/ -- PCOS Challenge announces its annual PCOS Awareness Symposium in the Atlanta, Georgia metro area on Sunday, September 21, 2014. The event will feature some of the world's leading Polycystic Ovary Syndrome experts, and bring together clinicians, researchers and hundreds of patients for a day of sharing experiences, insights and the latest updates about PCOS. Photo - http://photos.prnewswire.com/prnh/20140722/129570 Photo -...

2014-07-23 08:30:41

Strengthens Leadership Position in Treatments for Hunter syndrome and Commitment to MPS II Patient Community LEXINGTON, Massachusetts, July 23, 2014 /PRNewswire/ -- Shire plc (LSE: SHP, NASDAQ: SHPG), the global specialty biopharmaceutical company, and ArmaGen, a US privately held biotechnology company, today announced a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of both the...

2014-07-23 08:30:28

ArmaGen to Receive up to Approximately $225 Million Including Initial Upfront Payment of $15 Million in Cash and Equity, an Additional Equity Investment, R&D Funding, Development and Sales Milestones, in Addition to Future Royalties CALABASAS, Calif., July 23, 2014 /PRNewswire/ -- ArmaGen, a privately held biotechnology company focused on developing revolutionary therapies to treat severe neurological disorders, announced today that it has entered into a worldwide licensing and...

2014-07-23 08:30:17

CARLSBAD, Calif., July 23, 2014 /PRNewswire/ -- Essentialis announced today the receipt of a grant from the Foundation for Prader-Willi Research (FPWR) to support clinical study PC025, which is designed to evaluate the safety and efficacy of diazoxide choline controlled release tablets (DCCR) in obese Prader-Willi syndrome patients. The clinical study is being conducted at the University of California, Irvine under the direction of Dr. Virginia Kimonis. "We have found that the...

2014-07-22 08:30:52

SAN DIEGO, July 22, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced its wholly owned subsidiary, Sequenom Laboratories, will soon begin reporting on the presence of three additional clinically relevant subchromosomal microdeletions as part of the Enhanced Sequencing Series (ESS) for its MaterniT21(TM) PLUS laboratory-developed test. The microdeletions added include 11q deletion (Jacobsen...

2014-07-21 12:25:41

Subcommittee on Taxation and IRS Oversight of the US Senate Committee on Finance Will Convene a Congressional Hearing on NDSS' Top Legislative Priority, #PasstheABLEact, and NDSS Board Member Sara Wolff Set to Testify WASHINGTON, July 21, 2014 /PRNewswire/ -- Sara Wolff, a board member and self-advocate from the National Down Syndrome Society (NDSS), will testify before the Subcommittee on Taxation and IRS Oversight of the US Senate Committee on Finance on the Achieving a Better Life...

2014-07-18 16:23:11

Building on achievements and exploring new ways to find a cure for HIV/AIDS OTTAWA, July 18, 2014 /CNW/ - The Honourable Rona Ambrose, Minister of Health, will be in Melbourne next week at the 20(th) International AIDS Conference. Canada is making many significant contributions in the areas of testing and treatment guidance; vaccine development and research; and international partnerships to combat this deadly disease. The Conference is an opportunity for Canada to further...


Latest Syndromes Reference Libraries

Marfan's Syndrome
2013-07-19 15:22:33

Marfan's syndrome is a genetic disorder of the connective tissue that causes excessively tall stature and long extremities. It is carried by the gene FBN1, which encodes the connective protein fibrillin-1, and is a dominant trait. The human genetic makeup contains a pair of FBN1 genes, so because of its dominance, inheriting one affected FBN1 gene from either parent will result in Marfan's syndrome. It effects both males and females, and has no ethnic bias. It was named after Antoine Marfan,...

More Articles (1 articles) »
Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'